Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline
Source: SeekingAlpha
2025-08-08 14:49:44 ET
More on Verastem
- Verastem: The Market Is Ignoring The Progress
- Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
- Verastem Q2 2025 Earnings Preview
- Verastem Oncology gets FDA fast track status for cancer drug
- Seeking Alpha’s Quant Rating on Verastem
Read the full article on Seeking Alpha
For further details see:
Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline
Verastem Inc.
NASDAQ: VSTM
VSTM Trading
-5.06% G/L:
$5.725 Last:
618,855 Volume:
$5.88 Open:
VSTM Latest News
VSTM Stock Data
$424,027,638
66,108,246
1.4%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
